Area:
prion diseases, FFI, CJD, transgenic mice
We are testing a new system for linking grants to scientists.
The funding information displayed below comes from the
NIH Research Portfolio Online Reporting Tools and the
NSF Award Database.
The grant data on this page is limited to grants awarded in the United States and is thus partial. It can nonetheless be used to understand how funding patterns influence mentorship networks and vice-versa, which has deep implications on how research is done.
You can help! If you notice any innacuracies, please
sign in and mark grants as correct or incorrect matches.
Sign in to see low-probability grants and correct any errors in linkage between grants and researchers.
High-probability grants
According to our matching algorithm, Walker S Jackson is the likely recipient of the following grants.
| Years |
Recipients |
Code |
Title / Keywords |
Matching
score |
| 2004 — 2006 |
Jackson, Walker S |
F32Activity Code Description:
To provide postdoctoral research training to individuals to broaden their scientific background and extend their potential for research in specified health-related areas. |
Analysis of Cytoplasmic Prion Protein Toxicity @ Whitehead Institute For Biomedical Res
DESCRIPTION (provided by applicant): Evidence produced in the mid 1990's suggests that bovine spongiform encephalopathy (commonly known as mad cow disease) was probably transmitted to humans. The agents widely believed to be responsible for these diseases are abnormally shapened prion proteins. Along with an infectious route, humans can also develop prion diseases either sporadically or by expressing a mutant prion protein (penetrance approximately 100%). Recent work points to the cytosol as being the site of toxicity of prion proteins. Mutant prion proteins may be highly toxic because they have an increased probability of misfolding and therefore mislocalizing to the cytosol. To study the mechanism of increased toxicity of the mutant prion proteins and how it relates to cytosolic prion toxicity, ES cells will be genetically altered to express mutant prion proteins directly into the cytosol. These cell lines will be differentiated into neurons, gila, or fibroblasts and used to study the effects these mutations have on subcellular traffciking, degradation, and toxicity of PrP. The gene-targeting approach will allow for a high probability of equivalent expression of these constructs at the mRNA level. The selection of ES cells as a model system will permit efficient transition of cell culture experiments into mice.
|
0.912 |